Spyre Therapeutics Inc. is off to a good start in its goal to create the best combination therapy for inflammatory bowel disease, a group of chronic, relapsing autoimmune conditions of the digestive ...

In a move that could give patients quick access to drugs their doctors prescribe, the U.S. CMS is proposing a rule giving insurers no more than 24 hours to respond to urgent prior authorization ...

Synox Therapeutics Ltd. is preparing to file for FDA approval of emactuzumab in treating tenosynovial giant cell tumor (TGCT), after announcing positive top-line phase III results.

Revenio Group Oyj has agreed to acquire ophthalmic diagnostics company Visionix International SAS for an enterprise value of €290 million (US$339 million) as it looks to become a leading player in the ...

Biopharma deal value totaled $18.05 billion in March 2026, a pullback from $30.01 billion recorded in February and $31.16 billion in January, but broadly in line with prior years. The March total ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Alligator, Gan & Lee, Hologic, Grail, Junction, JW Pharmaceutical, Whitehawk.

The Scripps Research Institute has identified new baloxavir analogues and their prodrugs acting as new influenza cap-dependent endonuclease (CEN) inhibitors potentially useful for the treatment of ...

Vivatides Therapeutics Inc. has closed an oversubscribed $54 million series A financing to advance its work in extrahepatic ...

Solve Therapeutics Inc. has disclosed new antibody-drug conjugates (ADCs) comprising antibody or antigen binding fragments targeting trophoblast glycoprotein (TPBG; 5T4) linked to a cytotoxic drug and ...

Pemphigus vulgaris (PV) is a life-threatening autoimmune disease affecting the skin, causing painful erosions on the skin and mucous membranes. PV is caused by IgG4 autoantibodies that target ...

The top 10 biopharma stock gainers and losers for the week.

Unprecedented,” “remarkable” and “transformative” were just a few of the descriptives tossed out by Wall Street analysts in response to Revolution Medicines Inc.’s phase III readout, showing RAS ...